After Ultragenyx’s negative Phase 3 Angelman readout, rare neuro investors are tracking remaining RNA-targeted or related experimental programs for signals on next study design. Parallel attention also remains on CNS-adjacent modality bets entering or preparing for further evaluation in clinic. Collectively, these developments reinforce how rare disease pipelines are moving through heightened scrutiny—especially around endpoints, stratification, and durability of neurological outcome measures. For teams running similar development programs, the key near-term question is whether companies can de-risk mechanisms with clearer patient selection and more reliable clinical readouts.